Check Back Soon

Nystagmus Clinical Trials Near You

Find nystagmus clinical trials near you. Get notified when new research studies begin recruiting in your area.

No nystagmus trials are recruiting right now

We refresh our data every hour. New studies are added regularly — check back tomorrow or search our full database for the latest.

Active Trials in Related Eye Conditions

While we don't have nystagmus-specific trials right now, here are 20 recruiting studies in closely related conditions you may want to explore.

RecruitingMacular DegenerationNCT03683251

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) w...

10 locations(Phoenix, Phoenix, Phoenix)
1,000 participants
Hoffmann-La Roche
View Study Details
RecruitingMacular DegenerationNCT06541704

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (...

10 locations(Phoenix, Phoenix, Phoenix)
975 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingMacular DegenerationNCT06556368

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)...

10 locations(Gilbert, Phoenix, Scottsdale)
675 participants
Kodiak Sciences Inc
View Study Details
RecruitingMacular DegenerationNCT05407636

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by ...

10 locations(Phoenix, Phoenix, Scottsdale)
660 participants
AbbVie
View Study Details
RecruitingMacular DegenerationNCT04704921

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is character...

10 locations(Phoenix, Sun City, Little Rock)
630 participants
AbbVie
View Study Details
RecruitingGlaucomaNCT07075718

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant...

3 locations(Grand Junction, Oklahoma City, El Paso)
610 participants
Glaukos Corporation
View Study Details
RecruitingMacular DegenerationNCT05904028

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration....

10 locations(Glendale, Loma Linda, Oakland)
600 participants
Jaeb Center for Health Research
View Study Details
RecruitingDiabetic RetinopathyNCT04661358

Fenofibrate for Prevention of DR Worsening

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately s...

10 locations(Glendale, Huntington Beach, Loma Linda)
560 participants
Jaeb Center for Health Research
View Study Details
RecruitingGlaucomaNCT07082816

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT)....

10 locations(Dothan, Phoenix, Garden Grove)
470 participants
Alcon Research
View Study Details
RecruitingMacular DegenerationNCT07064759

Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration...

3 locations(Sun City, Hagerstown, Nashville)
400 participants
4D Molecular Therapeutics
View Study Details
RecruitingMacular DegenerationNCT06864988

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration...

10 locations(Phoenix, Scottsdale, Springdale)
400 participants
4D Molecular Therapeutics
View Study Details
RecruitingMacular DegenerationNCT06373731

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answ...

10 locations(Phoenix, Sun City, Huntington Beach)
360 participants
Stealth BioTherapeutics Inc.
View Study Details
RecruitingDry EyeNCT07025811

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy vo...

3 locations(Louisville, Memphis, Lynchburg)
350 participants
Hoffmann-La Roche
View Study Details
RecruitingCataractsNCT06922084

A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects

Prospective, randomized, multicenter, multi-arm, subject and vision-assessor-masked, two stage study with Stage 1 as a three-arm initial enrollment period, followed by Stage 2 as a head-to-head study ...

2 locations(Plymouth Meeting, Houston)
320 participants
Berkeley Eye Center
View Study Details
RecruitingMacular DegenerationNCT06635148

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies....

10 locations(Tucson, Fullerton, La Jolla)
311 participants
Janssen Research & Development, LLC
View Study Details
RecruitingUveitisNCT06431373

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU)....

10 locations(Phoenix, Bakersfield, Beverly Hills)
300 participants
Priovant Therapeutics, Inc.
View Study Details
RecruitingMacular DegenerationNCT06856577

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-...

10 locations(Gilbert, Phoenix, Phoenix)
284 participants
Adverum Biotechnologies, Inc.
View Study Details
RecruitingMacular DegenerationNCT06795048

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-w...

10 locations(Campbell, Santa Ana, Orlando)
274 participants
Hoffmann-La Roche
View Study Details
RecruitingMacular DegenerationNCT04567303

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in partici...

10 locations(Mesa, Phoenix, Encino)
251 participants
Hoffmann-La Roche
View Study Details
RecruitingGlaucomaNCT05695027

Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study

The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowerin...

3 locations(Palo Alto, New York, New York)
250 participants
Columbia University
View Study Details

Browse Related Conditions

About Nystagmus

Nystagmus is a condition of involuntary, rhythmic eye movements that can reduce vision and depth perception. It can be present from birth or develop later. Treatment depends on the cause and may include glasses, contact lenses, medications, or surgery.

Why Clinical Trials Matter for Nystagmus

Clinical trials are essential for advancing treatment options for nystagmus. Through research studies, scientists and doctors develop new therapies, improve existing treatments, and discover better ways to diagnose and manage the condition.

  • Access to new treatments: Participants may receive promising therapies before they are widely available
  • Expert medical care: Trial participants are closely monitored by specialized research teams
  • Contributing to science: Your participation helps advance medical knowledge for future patients
  • No cost: Most trial-related procedures and treatments are provided at no charge

What to Expect from Future Nystagmus Trials

While there are currently no actively recruiting trials for nystagmus on our platform, new studies are registered and begin recruiting regularly. Here's what you can expect when trials become available:

  1. Screening: Review eligibility criteria to see if you may qualify
  2. Consent: Learn about the study details, risks, and benefits before agreeing to participate
  3. Enrollment: Complete baseline assessments with the research team
  4. Treatment: Receive the study intervention with regular monitoring
  5. Follow-up: Continue check-ins to track your health outcomes

About This Data

Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.

Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.

Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov